Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume 57, Issue 3, Pages 635-643
Publisher
Informa UK Limited
Online
2015-10-13
DOI
10.3109/10428194.2015.1075019
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
- (2015) R. Chen et al. HAEMATOLOGICA
- A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma
- (2015) R. Chen et al. HAEMATOLOGICA
- A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia
- (2014) Michael J. Burke et al. AMERICAN JOURNAL OF HEMATOLOGY
- Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial
- (2014) Georg Hopfinger et al. ANNALS OF HEMATOLOGY
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies
- (2013) William R. Schelman et al. INVESTIGATIONAL NEW DRUGS
- In VitroandIn VivoTherapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome
- (2013) Liang Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation
- (2012) M. Gupta et al. BLOOD
- Management of indolent lymphoma: Where are we now and where are we going
- (2012) Matthew A. Lunning et al. BLOOD REVIEWS
- Cancer treatment and survivorship statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma
- (2012) M. Alsina et al. CLINICAL CANCER RESEARCH
- Non-Hodgkin lymphoma
- (2012) Kate R Shankland et al. LANCET
- Proteasome Inhibition and Combination Therapy for Non-Hodgkin's Lymphoma: From Bench to Bedside
- (2012) A. R. Mato et al. ONCOLOGIST
- The Unholy Trinity: Inflammation, Cytokines, and STAT3 Shape The Cancer Microenvironment
- (2011) Ning Li et al. CANCER CELL
- Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
- (2011) Mark Kirschbaum et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
- (2011) T. Hideshima et al. MOLECULAR CANCER THERAPEUTICS
- The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo
- (2010) G. Dasmahapatra et al. BLOOD
- Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma
- (2010) L. Paoluzzi et al. CLINICAL CANCER RESEARCH
- Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphoma
- (2010) P. L. Zinzani et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors
- (2010) Mark Andrew Dickson et al. INVESTIGATIONAL NEW DRUGS
- Beyond chemotherapy: new agents for targeted treatment of lymphoma
- (2010) Anas Younes Nature Reviews Clinical Oncology
- Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma
- (2009) Takashi Watanabe et al. CANCER SCIENCE
- Vorinostat enhances the antimyeloma effects of melphalan and bortezomib
- (2009) Richard A. Campbell et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Vorinostat in solid and hematologic malignancies
- (2009) David Siegel et al. Journal of Hematology & Oncology
- Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
- (2008) M. Crump et al. ANNALS OF ONCOLOGY
- Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma
- (2007) A. NAČINOVIĆ-DULETIĆ et al. International Journal of Laboratory Hematology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started